Literature DB >> 1375851

Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein.

F M Uckun1, S Haissig, J A Ledbetter, P Fidler, D E Myers, V Kuebelbeck, D Weisdorf, K Gajl-Peczalska, J H Kersey, N K Ramsay.   

Abstract

Sequential immunophenotypes of bone marrow (BM) and peripheral blood (PBL) lymphoid cells from 15 B-lineage acute lymphoblastic leukemia (ALL) patients who underwent autologous bone marrow transplantation (BMT) during complete remission were determined by dual-color immunofluorescence and multiparameter flow cytometry. Autografts were depleted of CD19+ B-cell precursors by an immunochemopurging protocol that combines B43-PAP, a potent anti-CD19 immunotoxin, and the cyclophosphamide congener 4-hydroperoxycyclophosphamide (4-HC). A marked interpatient variation was observed in the appearance and expansion of B-cell precursors repopulating the posttransplant marrow. The expression of CD10 and CD19 antigens during early B-cell ontogeny post-BMT preceded the expression of CD20, CD21, CD22, CD40, and sIgM. The surface antigen profiles of the emerging B-cell precursors were similar to those of fetal liver or fetal bone marrow B-cell precursors. Our comparisons of BM and PBL samples from patients in the early post-BMT period demonstrated that (1) PBL initially contains fewer B-lineage cells than does BM, and (2) circulating B-lineage lymphoid cells have a more mature immunophenotype than do BM B-lineage lymphoid cells. Comparison of the surface antigen profiles of day 30 versus day 100 or year 1 BM or PBL lymphoid cells showed an increase in the percentages of CD10+CD22- undifferentiated lymphocyte precursors, as well as CD19+sIgM- B-cell precursors (pre-pre-B), consistent with a time-dependent expansion of these B-cell precursor populations post-BMT. Importantly, the percentages of CD10+CD22+ and CD19+sIgM+ B-cell precursor (pre-B) populations also increased between 30 days and 1 year post-BMT, confirming the ability of emerging immature B-cell precursors to differentiate along the B-precursor pathway. The acquisition and expression of B-lineage differentiation antigens at different stages of the post-BMT B-cell ontogeny support the notion that the expression of these antigens is developmentally programmed. Similar to patients in previous autologous BMT studies, recipients of B-cell precursor-depleted autografts had normal or nearly normal serum immunoglobulin levels, suggesting that the maturing B-cell/plasma cell populations can produce and secrete immunoglobulins. The development of a functional CD19+ B-lineage lymphoid compartment in recipients of autografts which were depleted of CD19+ B-cell precursors corroborates the previously postulated existence of CD19- B-lineage lymphoid progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375851

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.

Authors:  Lisa Marie Serrano; Timothy Pfeiffer; Simon Olivares; Tontanai Numbenjapon; Jennifer Bennitt; Daniel Kim; David Smith; George McNamara; Zaid Al-Kadhimi; Joseph Rosenthal; Stephen J Forman; Michael C Jensen; Laurence J N Cooper
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

Review 2.  Translational Mini-Review Series on B cell subsets in disease. Reconstitution after haematopoietic stem cell transplantation - revelation of B cell developmental pathways and lineage phenotypes.

Authors:  M Bemark; J Holmqvist; J Abrahamsson; K Mellgren
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

Review 3.  Reconstitution of the immune system after hematopoietic stem cell transplantation in humans.

Authors:  Jan Storek; Michelle Geddes; Faisal Khan; Bertrand Huard; Claudine Helg; Yves Chalandon; Jakob Passweg; Eddy Roosnek
Journal:  Semin Immunopathol       Date:  2008-10-24       Impact factor: 9.623

4.  Defective B cell tolerance checkpoints in systemic lupus erythematosus.

Authors:  Sergey Yurasov; Hedda Wardemann; Johanna Hammersen; Makoto Tsuiji; Eric Meffre; Virginia Pascual; Michel C Nussenzweig
Journal:  J Exp Med       Date:  2005-02-28       Impact factor: 14.307

5.  CNS activity of Pokeweed anti-viral protein (PAP) in mice infected with lymphocytic choriomeningitis virus (LCMV).

Authors:  Fatih M Uckun; Larisa Rustamova; Alexei O Vassilev; Heather E Tibbles; Alexander S Petkevich
Journal:  BMC Infect Dis       Date:  2005-02-22       Impact factor: 3.090

Review 6.  Pokeweed antiviral protein, a ribosome inactivating protein: activity, inhibition and prospects.

Authors:  Artem V Domashevskiy; Dixie J Goss
Journal:  Toxins (Basel)       Date:  2015-01-28       Impact factor: 4.546

7.  Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression.

Authors:  Marina Kazantseva; Noelyn A Hung; Sunali Mehta; Imogen Roth; Ramona Eiholzer; Alison M Rich; Benedict Seo; Margaret A Baird; Antony W Braithwaite; Tania L Slatter
Journal:  Sci Rep       Date:  2017-05-08       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.